SAMUS THERAPEUTICS
Samus Therapeutics is a biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, including cancer and neurological disorders such as Alzheimer’s, Parkinson’s and chronic traumatic encephalopathy. Samus was established by Drs. Gabriela Chiosis and Larry Norton on research conducted at the Chiosis Laboratory at the Memorial Sloan Kettering Cancer Center, and at Rockefeller University and Weill Corn... ell Medicine. The Company’s lead oncology program, epichaperome complex inhibitor PU-H71, is being evaluated in Phase 1b and 1b/2 clinical studies in breast cancer and myelofibrosis. The Company’s lead CNS program, neurodegenerative epichaperome complex inhibitor PU-AD, is being studied in a biomarker study evaluating the distribution of the epichaperome complex in the brain of subjects with Alzheimer’s disease, with a Phase 1 therapeutic study to follow in 2018. In parallel with its therapeutics program, Samus is advancing the companion neurology and oncology PET/SPECT and flow cytometry biomarker programs PU-PET/SPECT and PU-CYT.
SAMUS THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2016-01-01
Address:
Topsfield, Massachusetts, United States
Country:
United States
Website Url:
http://www.samustherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
212-600-1902
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Current Employees Featured
Founder
Official Site Inspections
http://www.samustherapeutics.com Semrush global rank: 10.06 M Semrush visits lastest month: 55
- Host name: a67c48129651a0940.awsglobalaccelerator.com
- IP address: 13.248.213.45
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Samus Therapeutics"
Samus Therapeutics - Crunchbase Company Profile & Funding
Samus Therapeutics is a biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, …See details»
Samus Therapeutics - The Org
Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, including …See details»
Samus Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Samus Therapeutics, Inc. of Topsfield, MA. Get the latest business insights from Dun & Bradstreet.See details»
Samus Therapeutics - VentureRadar
Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics to enhance degradation of aberrant proteins which drive the pathology of …See details»
Pharma's Almanac: Nice Insight's Content Community
Samus Therapeutics Drug Discovery & Development Overview Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics targeting the …See details»
Samus Therapeutics Announces First Patient Dosed in Phase 1b …
Jan 5, 2022 Samus Therapeutics, Inc. is a privately held, Boston-based biotechnology company focused on addressing areas of high unmet medical need in cancer and neurodegenerative …See details»
Samus Therapeutics Company Profile - Office Locations ... - Craft
Samus Therapeutics is a biopharmaceutical company developing therapeutics targeting the epichaperome. It offers small molecule epichaperome inhibitors for the treatment of …See details»
Samus Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Nov 4, 2024 Explore Samus Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 9 clinical trials, and 5 literature, Drug:PU-H71, PU-AD. ... The statistics …See details»
Samus Therapeutics' CEO and Executive Team - The Org
Other teams at Samus Therapeutics. View all. JA. MS +6. Leadership Team. 9 members. The Org helps you hire great candidates. It takes less than ten minutes to set up your company page. …See details»
Samus Therapeutics Expands Clinical Development …
May 18, 2017 Samus Therapeutics is a privately-held, biopharmaceutical company focused on developing novel therapeutics and diagnostics targeting the epichaperome, a foundational protein complex emergent from multiple …See details»
Samus Therapeutics Announces Study Publication in …
Dec 1, 2021 Samus Therapeutics, Inc. is a privately held, Boston-based biotechnology company focused on addressing areas of high unmet medical need in cancer and neurodegenerative …See details»
Samus Therapeutics Receives IND Clearance from FDA for PU-AD …
May 11, 2021 Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing orally administered PU-AD (icapamespib) and PU-H71 (zelavespib) that target the …See details»
Samus Therapeutics Launches Phase 1 Trial of Tau-targeting Therapy
Jul 26, 2019 “In [Alzheimer’s] and tauopathy mouse models, inhibiting the epichaperome with PU-AD effected degradation of mutated hyperphosphorylated and aggregated tau protein,” …See details»
Clinical Trials Begin for PU-AD--Potential ... - Practical Neurology
Jul 24, 2019 The Food and Drug Administraion (FDA) has cleared the new drug application for PU-AD (Samus Therapeutics, Topsfield, MA), allowing a phase 1 clinical trial to begin. An …See details»
Samus Therapeutics Receives IND Clearance from FDA for PU-AD …
BOSTON, May 11, 2021 /PRNewswire/ -- Samus Therapeutics, Inc. ("Samus Therapeutics" or the "Company"), a privately held, Boston-based biopharmaceutical company developing …See details»
FDA Clears Samus Drug for Glioma Phase Ib Study - BioSpace
May 11, 2021 The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for PU-AD (icapamespib), an epichaperome inhibitor for recurrent …See details»
Samus Therapeutics Launches PU-AD Clinical Program in …
Jul 24, 2019 Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following …See details»
Samus Therapeutics Announces PU-H71 Granted Orphan Drug …
Jun 13, 2018 Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex …See details»
Samus Therapeutics Announces Publication of Study on …
Sep 2, 2021 Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing orally administered icapamespib (PU-AD, PU-HZ151) and zelavespib (PU-H71) …See details»
Samus Therapeutics Presents Phase 1 PU-AD Study Results at …
BOSTON, July 29, 2020 /PRNewswire/ -- Samus Therapeutics, Inc., a privately held, biopharmaceutical company developing small molecule epichaperome inhibitors , today …See details»